Copeptin and Arterial Hypotension in Critically Ill Paediatric and Neonatal Intensive Care Patients

N/ACompletedNCT03320967

Vincenzo Cannizzaro170 enrolled

Overview

Blood copeptin will be measured during the routine treatment of neonates, children and adolescents on the Intensive Care Unit of the University Children's Hospital Zurich at different time points (admission, 12, 24, 48, 96, 168 hours after admission). These values will be primarily analysed for their variability and their association with arterial hypotension. Blood samples will be drawn together with otherwise medically indicated blood withdrawals to avoid extra harm. Further, copeptin values will be compared to clinical and vital parameters, all of them open-label available during clinical routine. Copeptin's predictive value for patients' outcome will be analysed as secondary outcome.

Study Type

OBSERVATIONAL

Enrollment

170

Conditions

Arterial Hypotension in Critically Ill Neonatal and Pediatric Patients

Interventions

Copeptin in plasmaDIAGNOSTIC_TEST

Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.

Medical Language ↔ Plain English

Inclusion Criteria: * Age: first day of life until 18th birthday. * Ability of the care taker or the adolescent (if≥14 years of age) to understand verbal and written instructions and informed consent in German. Exclusion Criteria: * Care taker or adolescent (if ≥14 years of age) unwilling to give written informed consent. * Care taker or adolescent (if ≥14 years of age) not understanding German and without a family member able to translate. * Adolescent (if ≥14 years of age) unwilling to give written informed consent following sedation \< 24 hours. * Care takers of long-term sedated (\>24 hours) adolescents (if ≥14 years of age) unwilling to give written informed consent or not present within 24 hours.

Outcomes

Primary Outcomes

Blood copeptin in arterial normo- and hypotension

Average change of blood copeptin in patients with both arterial normo- and hypotension and different pathologies.

Time frame: Up to 168 hours.

Secondary Outcomes

Length of stay on the intensive care unit

Association of copeptin values with length of stay on the intensive care unit.

Time frame: Up to 168 hours.

Length of respiratory support

Association of copeptin values with length of respiratory Support.

Time frame: Up to 168 hours.

Length and dose of catecholamine therapy

Association of copeptin values with length and dose of catecholamine therapy.

Time frame: Up to 168 hours.

Rate of death

Rate of death at 28 days.

Time frame: Up to 168 hours.

Copeptin and Arterial Hypotension in Critically Ill Paediatric and Neonatal Intensive Care Patients

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes